NIBAN1

Summary

NIBAN1 (niban apoptosis regulator 1, HGNC:16784) is a protein-coding gene on chromosome 1q25.3, encoding Protein Niban 1 (Q9BZQ8). Regulates phosphorylation of a number of proteins involved in translation regulation including EIF2A, EIF4EBP1 and RPS6KB1.

This gene encodes a member of the family with sequence similarity 129 protein family. This gene is highly expressed in several cancer cells and may serve as a prognostic marker for certain cancers. The encoded protein may play a role in regulating p53-mediated apoptosis.

Source: NCBI Gene 116496 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 185 total
• MANE Select transcript: NM_052966

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16784
Approved symbol	NIBAN1
Name	niban apoptosis regulator 1
Location	1q25.3
Locus type	gene with protein product
Status	Approved
Aliases	NIBAN, GIG39
Ensembl gene	ENSG00000135842
Ensembl biotype	protein_coding
OMIM	619294
Entrez	116496

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 14 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000367511, ENST00000417056, ENST00000461167, ENST00000487074, ENST00000496299, ENST00000899938, ENST00000899939, ENST00000899940, ENST00000899941, ENST00000899942, ENST00000899943, ENST00000899944, ENST00000899945, ENST00000899946, ENST00000899947, ENST00000968385, ENST00000968386

RefSeq mRNA: 1 — MANE Select: NM_052966 NM_052966

CCDS: CCDS1364

Canonical transcript exons

ENST00000367511 — 14 exons

Exon	Start	End
ENSE00000822921	184823638	184823742
ENSE00000822923	184884633	184884800
ENSE00001128072	184890108	184890222
ENSE00001128077	184894075	184894206
ENSE00001152138	184899179	184899309
ENSE00001444835	184974302	184974508
ENSE00001908214	184791032	184796097
ENSE00003507472	184808074	184808235
ENSE00003562996	184818638	184818825
ENSE00003580688	184798079	184798190
ENSE00003597866	184831847	184831962
ENSE00003650397	184823167	184823329
ENSE00003692402	184803585	184803692
ENSE00003693348	184805946	184806056

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 99.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.9703 / max 3036.4979, expressed in 1657 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16286	19.4682	1478
16287	15.2167	1527
16285	2.5339	834
16288	0.7515	387

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood vessel layer	UBERON:0004797	99.49	gold quality
saphenous vein	UBERON:0007318	99.40	gold quality
parotid gland	UBERON:0001831	99.39	gold quality
heart right ventricle	UBERON:0002080	99.38	gold quality
vena cava	UBERON:0004087	99.17	gold quality
myocardium	UBERON:0002349	99.10	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.96	gold quality
left ventricle myocardium	UBERON:0006566	98.91	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.68	gold quality
seminal vesicle	UBERON:0000998	98.30	gold quality
right coronary artery	UBERON:0001625	98.07	gold quality
cauda epididymis	UBERON:0004360	97.92	gold quality
urethra	UBERON:0000057	97.88	gold quality
superficial temporal artery	UBERON:0001614	97.87	gold quality
mammary duct	UBERON:0001765	97.82	gold quality
trachea	UBERON:0003126	97.67	gold quality
nasal cavity epithelium	UBERON:0005384	97.51	gold quality
epithelium of mammary gland	UBERON:0003244	97.50	gold quality
calcaneal tendon	UBERON:0003701	97.37	gold quality
cartilage tissue	UBERON:0002418	97.20	gold quality
skin of hip	UBERON:0001554	97.09	gold quality
vastus lateralis	UBERON:0001379	96.90	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.89	gold quality
palpebral conjunctiva	UBERON:0001812	96.83	gold quality
blood	UBERON:0000178	96.79	gold quality
quadriceps femoris	UBERON:0001377	96.78	gold quality
biceps brachii	UBERON:0001507	96.75	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.73	gold quality
thoracic aorta	UBERON:0001515	96.72	gold quality
descending thoracic aorta	UBERON:0002345	96.69	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-7381	yes	677.37
E-MTAB-9221	yes	20.89
E-GEOD-81547	yes	20.79
E-MTAB-5061	yes	19.98
E-ANND-3	yes	19.53
E-CURD-97	no	569.21

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

143 targeting NIBAN1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-3119	99.92	71.34	2390

Literature-anchored findings (GeneRIF, showing 14)

• Niban expression is up-regulated in various types of thyroid tumors. (PMID:16949643)
• The expression of Niban frequently begins in the early stages of head and neck squamous carcinoma and remains upregulated throughout the carcinogenic process. Niban may be a good molecular marker of HNSCC. (PMID:19536772)
• Gene-expression data suggest a difference in expression between STT3A, Clorf24, and TFF3 in FAs versus carcinomas that may be detected from an FNA sample. Findings must be validated from preoperative FNAs in larger numbers (PMID:21520112)
• DDIT3, STT3A, ARG2 and FAM129A immunohistochemistry does not appear to be useful in the diagnosis of thyroid follicular neoplasias, as they do not reliably distinguish follicular thyroid carcinoma from follicular thyroid adenoma. (PMID:22157935)
• Data suggest that decreasing C1orf24 protein levels by restoring microRNA miR-106b function may have therapeutic implications. (PMID:26317551)
• We have shown that FAM129A is associated with variation in clinical asthma steroid responsiveness and that FAM129A modulates steroid responsiveness in lung epithelial cells. (PMID:29410046)
• results suggest a conditional regulation of KRT16 gene by ATF4 that may be inhibited in normal cells, but engaged during cancer progression. Potential roles of KRT16, FAM129A and HKDC1 genes upregulation in adaptive stress responses and pathologies are discussed (PMID:29420561)
• Our data suggest that, in normal thyroid cells, FAM129A induces autophagy in order to maintain cell homeostasis and provide substrates under starvation conditions. Instead, in thyroid cancer cells, decreased autophagy may help the cells to overcome cell death. FAM129A regulates autophagy in a cell- and/or context-dependent manner. (PMID:30400008)
• Silencing of Niban in HK-2 cells not only increased the AngII- and endoplasmic reticulum stress-induced apoptosis, but also promoted the expression of caspase 8, caspase 9, Bip, and Chop, suggesting that Niban protein is involved in apoptosis regulation in HK-2 cells, and most likely via caspase-dependent pathway. (PMID:31163002)
• One of the canonical Unfolded protein response branches, through ATF4 and its target gene FAM129A, is required for Prostate cancer growth and thus may serve as a novel therapeutic target. (PMID:31312022)
• MRNA and protein expression of FAM129A were negatively regulated by miR-135a. (PMID:31729558)
• MiR-4521 plays a tumor repressive role in growth and metastasis of hepatocarcinoma cells by suppressing phosphorylation of FAK/AKT pathway via targeting FAM129A. (PMID:35127170)
• The negative feedback loop FAM129A/CXCL14 aggravates the progression of esophageal cancer. (PMID:35776020)
• FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells. (PMID:37083136)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	niban1b	ENSDARG00000023053
danio_rerio	niban1a	ENSDARG00000042055
mus_musculus	Niban1	ENSMUSG00000026483
rattus_norvegicus	Niban1	ENSRNOG00000002403

Paralogs (2): NIBAN2 (ENSG00000136830), NIBAN3 (ENSG00000167483)

Protein

Protein identifiers

Protein Niban 1 — Q9BZQ8 (reviewed: Q9BZQ8)

Alternative names: Cell growth-inhibiting gene 39 protein, Protein FAM129A

All UniProt accessions (2): Q9BZQ8, H0Y7M9

UniProt curated annotations — full annotation on UniProt →

Function. Regulates phosphorylation of a number of proteins involved in translation regulation including EIF2A, EIF4EBP1 and RPS6KB1. May be involved in the endoplasmic reticulum stress response.

Subcellular location. Cytoplasm. Membrane.

Tissue specificity. Expressed in various types of thyroid tumor such as papillary thyroid carcinomas and oxyphilic thyroid tumors but not in normal thyroid tissue (at protein level). Strongly expressed in heart, skeletal muscle, pancreas, white blood cells and prostate with moderate expression in colon and spleen. Expressed in renal carcinoma cells but not in normal kidney.

Miscellaneous. ‘Niban’ means ‘second’ in Japanese.

Similarity. Belongs to the Niban family.

RefSeq proteins (1): NP_443198* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026088	Niban-like	Family
IPR059060	Niban_1/2/3_dom	Domain

Pfam: PF26086, PF26089

UniProt features (31 total): modified residue 7, compositionally biased region 6, sequence conflict 6, region of interest 5, sequence variant 4, initiator methionine 1, chain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BZQ8-F1	70.11	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 579, 582, 596, 602, 646, 708, 926, 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 357 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, KOBAYASHI_EGFR_SIGNALING_24HR_UP, BENPORATH_ES_WITH_H3K27ME3, GOBP_REGULATION_OF_PHOSPHORYLATION, XU_GH1_AUTOCRINE_TARGETS_UP, AAGTCCA_MIR422B_MIR422A, PEREZ_TP63_TARGETS, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS

GO Biological Process (5): negative regulation of protein phosphorylation (GO:0001933), positive regulation of protein phosphorylation (GO:0001934), response to endoplasmic reticulum stress (GO:0034976), positive regulation of translation (GO:0045727), regulation of translation (GO:0006417)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of protein phosphorylation	2
protein phosphorylation	2
translation	2
negative regulation of protein modification process	1
negative regulation of phosphorylation	1
positive regulation of protein modification process	1
positive regulation of phosphorylation	1
cellular response to stress	1
regulation of translation	1
positive regulation of gene expression	1
positive regulation of protein metabolic process	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1
extracellular vesicle	1

Protein interactions and networks

STRING

1702 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NIBAN1	STT3A	P46977	505
NIBAN1	OSBPL10	Q9BXB5	479
NIBAN1	CCDC179	H3BU77	477
NIBAN1	EPHA2	P29317	380
NIBAN1	TMEM100	Q9NV29	361
NIBAN1	CFAP92	Q9ULG3	351
NIBAN1	ACTC1	P04270	350
NIBAN1	SYNPO2	Q9UMS6	329
NIBAN1	CLMN	Q96JQ2	315
NIBAN1	EFL1	Q7Z2Z2	294
NIBAN1	ZNF777	Q9ULD5	290
NIBAN1	CHAC1	Q9BUX1	290
NIBAN1	RHOF	Q9HBH0	282
NIBAN1	HES2	Q9Y543	263
NIBAN1	CRISPLD2	Q9H0B8	258

IntAct

22 interactions, top by confidence:

A	B	Type	Score
NIBAN1	FHL2	psi-mi:“MI:0915”(physical association)	0.720
FHL2	NIBAN1	psi-mi:“MI:0915”(physical association)	0.720
NPM1	NIBAN1	psi-mi:“MI:0915”(physical association)	0.600
NIBAN1	NPM1	psi-mi:“MI:0407”(direct interaction)	0.600
NPM1	NIBAN1	psi-mi:“MI:0407”(direct interaction)	0.600
NIBAN1	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
DDIT4L	NIBAN1	psi-mi:“MI:0915”(physical association)	0.560
AKT1	NIBAN1	psi-mi:“MI:0915”(physical association)	0.540
AKT1	NIBAN1	psi-mi:“MI:0217”(phosphorylation reaction)	0.540
ECE1	NIBAN1	psi-mi:“MI:0915”(physical association)	0.370
	ESYT2	psi-mi:“MI:0914”(association)	0.350
NIBAN1	FHL2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (36): FAM129A (Two-hybrid), FAM129A (Affinity Capture-MS), FAM129A (Affinity Capture-RNA), FAM129A (Two-hybrid), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), FAM129A (Proximity Label-MS), AKT1 (Affinity Capture-Western), NPM1 (Affinity Capture-Western)

ESM2 similar proteins: A1A4V9, A4IFI1, A8E4X8, B0BMZ6, G5E8P0, O75161, P18302, P59017, P59240, P85299, P97432, Q14596, Q2HJA5, Q2T9R2, Q3B7M3, Q3MHU5, Q3U0L2, Q3ZBK7, Q3ZK22, Q499E4, Q501R9, Q53GS7, Q569K6, Q58DT5, Q5FVG6, Q5RAS2, Q5SPX1, Q5T7N3, Q5XI52, Q60698, Q60943, Q6NZQ0, Q6P9J5, Q80U62, Q812A5, Q8C0R7, Q8CC12, Q8IWY9, Q8IYY4, Q8N6L0

Diamond homologs: B4F7E8, Q3UW53, Q8R1F1, Q96TA1, Q9BZQ8, Q9ESN0

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
AKT	unknown	NIBAN1	phosphorylation
AKT1	unknown	NIBAN1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

185 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	157
Likely benign	13
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

3578 predictions. Top by Δscore:

Variant	Effect	Δscore
1:184798073:TCTTA:T	donor_loss	1.0000
1:184798074:CTTA:C	donor_loss	1.0000
1:184798075:TTA:T	donor_loss	1.0000
1:184798076:TA:T	donor_loss	1.0000
1:184798078:CCTTT:C	donor_gain	1.0000
1:184798206:T:TC	acceptor_gain	1.0000
1:184803575:ATCC:A	donor_gain	1.0000
1:184803583:A:AC	donor_gain	1.0000
1:184803584:C:CC	donor_gain	1.0000
1:184806053:TTAG:T	acceptor_gain	1.0000
1:184806057:C:CC	acceptor_gain	1.0000
1:184806065:C:CT	acceptor_gain	1.0000
1:184808069:CCCA:C	donor_loss	1.0000
1:184808070:CCA:C	donor_loss	1.0000
1:184808072:A:AT	donor_loss	1.0000
1:184808072:ACCT:A	donor_gain	1.0000
1:184808073:C:CT	donor_loss	1.0000
1:184808073:CCTC:C	donor_gain	1.0000
1:184808075:T:TA	donor_gain	1.0000
1:184808103:C:CT	donor_gain	1.0000
1:184808234:TG:T	acceptor_gain	1.0000
1:184808243:T:C	acceptor_gain	1.0000
1:184808246:G:C	acceptor_gain	1.0000
1:184808246:G:GC	acceptor_gain	1.0000
1:184823163:TGA:T	donor_loss	1.0000
1:184823164:GA:G	donor_loss	1.0000
1:184823165:A:AG	donor_loss	1.0000
1:184823330:C:CC	acceptor_gain	1.0000
1:184823649:T:TA	donor_gain	1.0000
1:184831841:TATTA:T	donor_loss	1.0000

AlphaMissense

6120 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:184894137:A:G	W86R	0.998
1:184894137:A:T	W86R	0.998
1:184798161:A:C	F528L	0.997
1:184798161:A:T	F528L	0.997
1:184798163:A:G	F528L	0.997
1:184823304:A:T	V283D	0.996
1:184823646:A:G	W272R	0.996
1:184823646:A:T	W272R	0.996
1:184823714:A:G	L249P	0.996
1:184831918:C:G	A216P	0.996
1:184823653:C:A	K269N	0.995
1:184823653:C:G	K269N	0.995
1:184899271:A:C	Y32D	0.995
1:184803664:C:G	R492P	0.994
1:184803675:G:C	S488R	0.994
1:184803675:G:T	S488R	0.994
1:184803677:T:G	S488R	0.994
1:184899282:A:G	F28S	0.994
1:184796061:A:G	L568S	0.993
1:184823656:T:A	R268S	0.993
1:184823656:T:G	R268S	0.993
1:184805946:C:A	K482N	0.992
1:184805946:C:G	K482N	0.992
1:184818750:A:G	L354P	0.992
1:184823702:A:G	L253P	0.992
1:184798186:A:G	L520P	0.991
1:184805953:A:T	V480D	0.991
1:184805956:C:G	R479P	0.990
1:184806044:C:G	A450P	0.990
1:184818734:G:C	S359R	0.990

dbSNP variants (sampled 300 via entrez): RS1000011072 (1:184943978 T>C), RS1000014237 (1:184948293 T>G), RS1000042745 (1:184915313 T>C), RS1000046788 (1:184947909 T>C), RS1000060424 (1:184902899 A>G), RS1000086643 (1:184814054 A>T), RS1000109076 (1:184878681 A>T), RS1000119292 (1:184802913 G>A,C), RS1000136654 (1:184861434 C>T), RS1000146962 (1:184812755 C>T), RS1000188227 (1:184792996 T>G), RS1000205849 (1:184894441 A>G), RS1000289521 (1:184855443 A>G), RS1000305736 (1:184820562 C>T), RS1000313111 (1:184897772 A>G)

Disease associations

OMIM: gene MIM:619294 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST001762_684	Obesity-related traits	4.000000e-06
GCST004049_12	Cough in response to angiotensin-converting enzyme inhibitor drugs	4.000000e-07
GCST004735_20	Epstein-Barr virus copy number in lymphoblastoid cell lines	9.000000e-06
GCST008521_3	Bitter beverage consumption	1.000000e-06
GCST008745_89	Estimated glomerular filtration rate in non-diabetics	5.000000e-09
GCST008747_3	Estimated glomerular filtration rate	1.000000e-11
GCST008747_54	Estimated glomerular filtration rate	4.000000e-12
GCST009997_4	Thyroid volume in Hashimoto’s thyroiditis	1.000000e-07
GCST010145_7	Cerebrospinal fluid immune biomarker levels	1.000000e-08
GCST010396_266	Gut microbiota (bacterial taxa, hurdle binary method)	3.000000e-07
GCST90000025_837	Appendicular lean mass	4.000000e-12
GCST90002395_546	Mean platelet volume	1.000000e-10

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005325	response to angiotensin-converting enzyme inhibitor
EFO:0010089	bitter beverage consumption measurement
EFO:0010596	monocyte chemotactic protein 1 measurement
EFO:0007874	gut microbiome measurement
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

102 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression, increases methylation	5
Valproic Acid	increases expression	5
Cyclosporine	increases expression	4
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	3
Tretinoin	decreases expression, increases expression	3
perfluorooctanoic acid	increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
bisphenol S	increases expression, affects cotreatment	2
bisphenol AF	decreases expression, increases expression	2
Cisplatin	increases expression, affects response to substance	2
Copper	affects binding, increases expression	2
Dexamethasone	increases expression, decreases expression, affects cotreatment	2
Estradiol	affects cotreatment, increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
methylmercuric chloride	increases expression	1
propionaldehyde	increases expression	1
pirinixic acid	increases activity, increases expression, affects binding	1
sodium arsenate	decreases expression	1
titanium dioxide	decreases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
hydroxyhydroquinone	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
o,p’-DDT	increases expression	1
afimoxifene	increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.